Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide

Anja Kraemer, Stefan Hauser, Young Kim, Marcus Gorschlüter, Stefan C. Müller, Peter Brossart & Ingo G. H. Schmidt-Wolf
Background: The highly vascular nature of renal carcinoma cells suggests that inhibition of angiogenesis may be beneficial in this disease. Thalidomide has been described as inhibitor of the fibroblast growth factor (FGF) and the vascular endothelial growth factor (VEGF). Therefore and in consideration of the promising response rates of the combination of IL-2, IFN-alpha and 5-FU [ref:1] in metastatic renal cancer, we found it reasonable to test the combination of 5-FU and thalidomide. Thus, we...